15th Mar 2007 07:01
Sinclair Pharma PLC15 March 2007 Not for release or distribution or publication in whole or part in or into the United States, Canada, Japan or Australia Sinclair Pharma plc - Proposed move from AIM to the Official List and notice of intended cancellation of admission to AIM 15 March 2007. Godalming, UK. Sinclair Pharma plc ("the Company") todayannounces that as indicated in its AGM statement of 15 November 2006, theCompany intends to apply for admission of its ordinary shares to the OfficialList of the UK Listing Authority ("Official List") and to trading on the LondonStock Exchange's market for listed securities, and to trading on Eurolist byEuronext Paris, the regulated market of Euronext Paris SA ("Euronext Paris").This will be through an introduction of its existing ordinary shares, with nonew shares being issued. Pursuant to Rule 41 of the AIM Rules for Companies, the Company hereby givesnotice of the intended cancellation of trading of its ordinary shares on the AIMmarket of the London Stock Exchange. It is expected that the cancellation of the trading in the ordinary shares onAIM will be simultaneous with admission to the Official List and to trading onthe London Stock Exchange's market for listed securities and Eurolist byEuronext Paris in April. This will happen no earlier than 16 April 2007 on theOfficial List, and no earlier than 19 April 2007 on Eurolist by Euronext Paris,subject to the receipt of necessary approvals from the relevant regulatoryauthorities. The Directors believe that the move to the Official List is appropriate to thegrowth and ambition of the Company. The new listings are expected to increaseliquidity in the ordinary shares, and enhance the domestic and internationalprofile of the Company. In recent years, the Company has expanded itsinternational presence, and now has significant and expanding activities incontinental Europe. A secondary listing on Euronext Paris will reflect theCompany's growing commercial presence in these territories. -ends- Notes to editors: Sinclair Pharma plc Sinclair Pharma plc is an international specialty pharmaceutical company. Ithas a growing sales and marketing operation that is already present in France,Italy, UK, Spain and Portugal, and a complementary marketing partner networkthat spans more than 65 countries. Sinclair has proven expertise in acquiring or developing commercially attractiveand undervalued products, registering these products and bringing them to marketwithin a short time frame. The company focuses on niche therapeutic areas andits current portfolio includes products for dermatological conditions and oralhealth. Enquiries: Sinclair Pharma plc +44 (0)1483 410600Dr Michael Flynn, CEOJerry Randall, CFOZoe McDougall, Director of Communications Piper Jaffray +44 (0)20 3142 8700David RasoulyWill Carnwath Capital MS&L +44 (0)20 7307 5336Mary Clark This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Sinclair Pharma